Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: A report from the Children's Oncology Group

Blood

Volumn 116, Issue 7, 2010, Pages 1045-1050

  Maloney, Kelly W ^a   Carroll, William L ^b   Carroll, Andrew J ^c   Devidas, Meenakshi ^d   Borowitz, Michael J ^e   Martin, Paul L ^f   Pullen, Jeanette ^g   Whitlock, James A ^h   Willman, Cheryl L ⁱ   Winick, Naomi J ^j   Camitta, Bruce M ^k   Hunger, Stephen P ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF NEW MEXICO   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k CHILDREN S HOSPITAL OF WISCONSIN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; ONCOPROTEIN; TCF3-PBX1 FUSION PROTEIN, HUMAN; TEL-AML1 FUSION PROTEIN; TRANSCRIPTION FACTOR RUNX1;

CHILD; CHROMOSOME 10; CHROMOSOME 4; CHROMOSOME ABERRATION; DOWN SYNDROME; FEMALE; GENETICS; HUMAN; MALE; NEOPLASM, RESIDUAL; PATHOLOGY; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TRISOMY;

CHILD; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 4; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DOWN SYNDROME; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; MALE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TRISOMY;

EID: 77954491626     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-235291     Document Type: Article

References (27)

1. Lange B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol. 2000;110(3):512-524.
2. Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child. 1990;65(2):212-216. (Pubitemid 20057814)
3. Ragab AH, Abdel-Mageed A, Shuster JJ, et al. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down's syndrome: a Pediatric Oncology Group study. Cancer. 1991;67(4):1057-1063.
4. Pui CH, Raimondi SC, Borowitz MJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol. 1993;11(7):1361-1367.
5. Dordelmann M, Schrappe M, Reiter A, et al. Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Munster Group. Leukemia. 1998;12(5):645-651.
6. Chessells JM, Harrison G, Richards SM, et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child. 2001;85(4):321-325. (Pubitemid 32929599)
7. Whitlock JA, Sather HN, Gaynon P, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005;106(13):4043-4049. (Pubitemid 41775907)
8. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128(6):797-804. (Pubitemid 40444872)
9. Whitlock JA. Down syndrome and acute lymphoblastic leukaemia. Br J Haematol. 2006;135(5):595-602. (Pubitemid 44674071)
10. Bassal M, La MK, Whitlock JA, et al. Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005;44(1):21-28. (Pubitemid 39602561)
11. Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111(3):1575-1583. (Pubitemid 351213448)
12. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
13. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996;14(1):18-24.
14. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338(23):1663-1671.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Peto R, Peto T. Asymptotically efficient rank invariant test procedure. J R Stat Soc. 1972;135:185-198.
17. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109(3):926-935.
18. Arico M, Ziino O, Valsecchi MG, et al. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer. 2008;113(3):515-521.
19. Sutcliffe MJ, Shuster JJ, Sather HN, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. Leukemia. 2005;19(5):734-740.
20. Robison LL, Nesbit ME Jr, Sather HN, et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Childrens Cancer Study Group. J Pediatr. 1984;105(2):235-242.
21. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009;41(11):1243-1246.
22. Hertzberg L, Vendramini E, Ganmore I, et al. Down syndrome acute lymphoblastic leukemia: a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2. A report from the International BFM Study Group. Blood. 2009;115(5):1006-1017.
23. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, hispanic/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 2010;115(26):5312-5321.
24. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009;106(23):9414-9418.
25. Gaikwad A, Rye CL, Devidas M, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009;144(6):930-932.
26. Kearney L, Gonzalez De Castro D, Yeung J, et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood. 2009;113(3):646-648.
27. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372(9648):1484-1492.